Berkeley App Notes
-
Screen Candidates And Select Better Leads For Developing Therapeutic Antibodies
5/19/2022
We demonstrate a workflow that can be used to access broad plasma cell diversity and rapidly down-select lead candidates with functional profiling.
-
Achieve FDA-Accepted Monoclonality Assurance In Cell Line Development
8/20/2021
The Opto Cell Line development workflow provides >99% probability of clonality from a single automated round of cloning, while in-process imaging provides direct evidence of clonal derivation.
-
Improve Product Quality As Early As Clone Selection
8/19/2021
Product aggregation is a major stability, efficacy, and safety concern in the manufacturing of antibody therapeutics. This assay enables detection of product aggregates within days of single cell cloning.
-
Directly Link Phenotype To Gene Expression To Design Better Therapies
5/17/2021
Understanding the genetic mechanisms of T-cell polyfunctionality could be critical for developing effective therapeutics. This workflow makes it possible to identify these mechanisms.
-
Simplify Single Cell Natural Killer Cell Cytotoxicity & ADCC Mediation
1/22/2021
This application note demonstrates how NK cell function can be assessed at the single-cell level to characterize both cytotoxicity and ADCC mediation in the presence of target cells.
-
Directly Link T Cell Phenotype And Function To Genotype
1/22/2021
Current techniques used to assess T cell function only allow us to draw correlative conclusions. This application note demonstrates how the Berkeley Lights platform can directly link phenotype to genotype to identify differences in CAR T cell killing kinetics as well as to recover TCR sequences that are associated with desired killing behavior.
-
Identify And Select Optimal CAR T Phenotypes
1/22/2021
This application note demonstrates how the Berkeley Lights platform can be used to identify single T cells that maintain proliferative ability while secreting specific cytokine combinations and exhibiting desired tumor killing activity.